Publications by authors named "Bernard Scallon"

Claim this Profile
F
Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality.
Susan H Tam, Stephen G McCarthy, Anthony A Armstrong, Sandeep Somani, Sheng-Jiun Wu, Bernard J Scallon

Antibodies (Basel)· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.
David J Shealy, Ann Cai, Kim Staquet, Audrey Baker, Eilyn R Lacy, Bernard J Scallon

MAbs· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities.
Susan H Tam, Stephen G McCarthy, Kerry Brosnan, Kenneth M Goldberg, Bernard J Scallon

MAbs· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric antibodies with extended half-life in ferrets.
Thomas C Nesspor, Bernard Scallon

Influenza Other Respir Viruses· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Omid Vafa, Gary L Gilliland, Randall J Brezski, Brandy Strake, Teresa Wilkinson, Bernard Scallon

Methods· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.
Jacqueline M Benson, David Peritt, Bernard J Scallon, George A Heavner, David J Shealy

MAbs· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineering host cell lines to reduce terminal sialylation of secreted antibodies.
Michael F Naso, Susan H Tam, Bernard J Scallon, T Shantha Raju

MAbs· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain.
T Shantha Raju, Bernard Scallon

Biotechnol Prog· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative in vivo comparisons of the Fc gamma receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody.
Bernard Scallon, Stephen McCarthy, Jennifer Radewonuk, Ann Cai, Michael Naso

Int Immunopharmacol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.
Bernard J Scallon, Susan H Tam, Stephen G McCarthy, Ann N Cai, T Shantha Raju

Mol Immunol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of antibody therapeutics and antibody-related technologies for oncology.
Bernard J Scallon, Linda A Snyder, G Mark Anderson, Qiming Chen, Li Yan

J Immunother· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain.
T Shantha Raju, Bernard J Scallon

Biochem Biophys Res Commun· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of an extra immunoglobulin domain to two anti-rodent TNF monoclonal antibodies substantially increased their potency.
Bernard Scallon, Ann Cai, Jennifer Radewonuk, Michael Naso

Mol Immunol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors.
Kate A Scott, Robert J Moore, Caroline H Arnott, Nick East, Richard G Thompson, Bernard J Scallon

Mol Cancer Ther· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis